Canon Celebrates Seventh Consecutive Win for uniFLOW Online with BLI Pick Award
Canon Celebrates Seventh Consecutive Win for uniFLOW Online with BLI Pick Award
Melville, NY, April 14, 2025 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, has once again been recognized for the uniFLOW Online solution it offers, earning the Buyers Lab (BLI) Pick Award for Outstanding Cloud Output Management Solution for the seventh consecutive year from Keypoint Intelligence.
uniFLOW Online, which introduced Remote Device Access1, builds on its reputation for providing organizations with the ability to track and control print, scan, and copy activities from virtually anywhere, all through a single cloud-based platform. This new feature enables IT teams to provide real-time support to compatible MFP devices remotely, helping to limit the need to send technicians for on-site uniFLOW Online technical support. This is designed to help enhance uptime and help businesses get back to work faster.
In addition to Remote Device Access, uniFLOW Online strengthened its integrations with Microsoft SharePoint® and iManage® Cloud, and added capabilities such as scheduled email reports and additional scan-to-email functionality.2 These innovations further enhance the solution's flexibility and its ability to meet the demands of modern work environments.
'We are extremely proud to receive this honor for the seventh consecutive year,' said Kiyoshi Oka, executive vice president and general manager, marketing strategy unit, Canon U.S.A., Inc. 'This award underscores Canon's commitment to delivering amazing print and scan solutions that are flexible, include security features and are tailored for today's evolving workplace. With ongoing improvements to the uniFLOW Online platform, we are able to provide a solution that offers virtually seamless, efficient support to businesses no matter where their teams are working.'
'Keypoint Intelligence analysts have long been impressed with the steady evolution of uniFLOW Online and its reliable, feature-rich capabilities year after year,' said Jamie Bsales, principal analyst, Keypoint Intelligence. 'The solution continues to provide businesses with print management with security features, mobile device support, and detailed tracking, while constantly improving and adapting to changing market needs.'
To learn more about the uniFLOW Online solution, please visit usa.canon.com/business/printing/software-solutions/uniflow-online.
About Keypoint Intelligence
For 60 years, clients in the digital imaging industry have relied on Keypoint Intelligence for independent hands-on testing, lab data, and extensive market research to drive their product and sales success. Keypoint Intelligence has been recognized as the industry's most trusted resource for unbiased information, analysis, and awards due to decades of analyst experience. Customers have harnessed this mission-critical knowledge for strategic decision-making, daily sales enablement, and operational excellence to improve business goals and increase bottom lines.
About Canon U.S.A., Inc.
Canon U.S.A., Inc. is a leading provider of consumer, business-to-business, and industrial digital imaging solutions to the United States, Latin America, and the Caribbean markets. With approximately $28.5 billion in global revenue, its parent company, Canon Inc., as of 2024 has ranked in the top-10 for U.S. patents granted for 41 consecutive years. † Canon U.S.A. is dedicated to its Kyosei philosophy of social and environmental responsibility. To learn more about Canon, visit www.usa.canon.com and connect with us on LinkedIn at www.linkedin.com/company/canonusa.
† Based on patent counts issued by the United States Patent and Trademark Office and compiled by IFI CLAIMS Patent Services.
1 Available on imageRUNNER ADVANCE Gen3 or higher. Access requires an internet connection, and each device requires an active Cloud Print and Scan Type 1 license subscription. Allows up to two connections per tenant. Remote Access will automatically disconnect after 20 minutes or manually terminate the connection.
2 Subscription to a third party cloud service required. Subject to third party cloud service providers terms and conditions.
Specifications and availability are subject to change without notice.
Many variables can impact the security of a customer's device and data. Canon does not warrant that the use of features will prevent malicious attacks, or prevent misuse of devices or data or other security issues.
All referenced product names, and other marks, are trademarks of their respective owners.
uniFLOW Online 2024 was evaluated for the BLI Pick Award.
Attachment
Canon Celebrates Seventh Consecutive Win for uniFLOW Online with BLI Pick Award
CONTACT: Nicole Esan Canon U.S.A., Inc. 6313302136 niesan@cusa.canon.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
a minute ago
- Associated Press
Rapid Micro Biosystems Reports Second Quarter 2025 Financial Results
LEXINGTON, Mass., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the 'Company'), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the second quarter ended June 30, 2025. 'Our second quarter results reflect broad-based, consistent execution across the business,' said Robert Spignesi, President and CEO. 'Total revenue increased 10%, driven by an 18% increase in Service revenue. Product revenue increased by 6%, led by mid-teens growth in consumables. With continued strong customer interest in Growth Direct and meaningful progress across our broader business, we are reiterating our full-year 2025 revenue guidance.' 'In addition, this morning we announced a new five-year, $45 million term loan facility, with $20 million funded upfront with highly favorable terms, including no financial or liquidity covenants,' continued Spignesi. 'This facility significantly strengthens our financial position and reinforces our ability to achieve positive cash flow. Our strategic priorities remain unchanged, and this capital supports our continued focus on delivering significant long-term revenue growth, gross margin expansion and shareholder value.' Second Quarter Financial Results Total revenue for the second quarter of 2025 increased 10% to $7.3 million compared to $6.6 million in the second quarter of 2024. The Company placed four new Growth Direct® systems and completed the validation of two customer systems compared to five placements and five validations in the second quarter of 2024. Product revenue increased by 6% to $4.8 million, compared to $4.5 million in the second quarter of 2024. Service revenue increased by 18% to $2.5 million, compared to $2.1 million in the second quarter of 2024. Recurring revenue increased by 15% to $4.4 million, compared to $3.8 million in the second quarter of 2024. Total cost of revenue was $7.0 million in the second quarter of 2025, an increase of 3% compared to $6.8 million in the second quarter of 2024. Gross margin was positive 4%, or positive $0.3 million, compared to negative 3%, or negative $0.2 million in the second quarter of 2024. Total operating expenses decreased by 6% to $12.4 million in the second quarter of 2025, compared to $13.2 million in the second quarter of 2024. General and administrative expenses increased 4%, research and development expenses decreased by 14%, and sales and marketing expenses decreased by 14%, in each case compared to the second quarter of 2024. Net loss for the second quarter of 2025 was $11.9 million, compared to $12.6 million in the second quarter of 2024. Net loss per share for the second quarter of 2025 was $0.27, compared to $0.29 in the second quarter of 2024. Cash, cash equivalents, short-term investments, and restricted cash were approximately $32 million as of June 30, 2025. 2025 Outlook The Company is reaffirming its full year 2025 total revenue guidance of at least $32.0 million. Loan Facility In a separate release issued today, the Company announced that it has entered into a five-year, $45 million term loan facility with Trinity Capital Inc. The Company received $20 million at close through the first tranche and has access to two additional tranches totaling $20 million, subject to the achievement of certain commercial and operational milestones. A fourth tranche of $5 million is available at the lender's discretion. For additional details regarding this facility, please refer to the related press release at Webcast Details The Company will host a conference call before the market opens today, August 12, 2025, at 8:30 a.m. ET to discuss its second quarter 2025 financial results. The live call is accessible on the Company's website at and will be archived and available for replay for one year. About Rapid Micro Biosystems Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company's flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control ('MQC') testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered in Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn. Rapid Micro Biosystems intends to use the Investor Relations page of its website as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Accordingly, investors should monitor its website in addition to following press releases, filings with the Securities and Exchange Commission ('SEC'), public conference calls, presentations and webcasts. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company's guidance, including with respect to full year 2025 total revenue and number of Growth Direct placements; the Company's goal of achieving cash flow breakeven; the Company's newly-announced debt facility; the Company's ability to reduce product costs, and improve manufacturing efficiency and service productivity; and the Company's ability to advance its priorities of accelerating Growth Direct system placements, improving gross margins and innovating new products. In some cases, you can identify forward-looking statements by terminology such as 'outlook,' 'aim,' 'anticipate,' 'assume,' 'believe,' 'contemplate,' 'continue,' 'could,' 'due,' 'estimate,' 'expect,' 'goal,' 'intend,' 'may,' 'objective,' 'plan,' 'predict,' 'potential,' 'positioned,' 'seek,' 'should,' 'target,' 'will,' 'would' and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to risks related to, the Company's ability to achieve positive cash flow; the Company's ability to achieve its business objectives; the Company's significant losses since inception; the Company's ability to meet its publicly announced guidance and other expectations about its business and operations; the impact of the Company's existing and any future indebtedness on its ability to operate its business; the Company's ability to access any future tranches under its debt facility and to comply with all of its obligations thereunder, the Company's limited experience in marketing and sales and the effectiveness of its sales processes; the Company's need to develop new products and adapt to technological changes; the Company's ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company's ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company's ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; risks associated with macroeconomic events and uncertainty, including with respect to tariff and trade policy in the U.S. and abroad, as well as activity in the Company's industry and in the general economy; and the other important factors outlined under the caption 'Risk Factors' in the Company's Quarterly Report on Form 10-Q filed with the SEC, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at and the Investor Relations page of its website at Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law. Investor Contact Michael Beaulieu, CFA Vice President, Investor Relations and Corporate Communications [email protected] Media Contact [email protected]
Associated Press
a minute ago
- Associated Press
Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update
MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on August 12, 2025, to review financial performance and provide a corporate update. Dr. Roger Jeffs, Liquidia's Chief Executive Officer, said: 'The second quarter was a defining period for Liquidia with the FDA approval and rapid commercial launch of YUTREPIA™ (treprostinil) inhalation powder. More than 350 physicians across the country have already prescribed YUTREPIA to treat patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), including those new to prostacyclin treatment or transitioning from Tyvaso®, Tyvaso DPI®, and even from oral prostacyclins. In the 11 weeks since approval, we've recorded over 900 unique patient prescriptions leading to more than 550 patient starts. This initial demand has exceeded my own high expectations. The robust and increasing uptake reflects a clear need for more flexible and better-tolerated prostacyclin therapies. We've already seen broad demand across both indications from both cardiologists and pulmonologists. Notably, this early momentum has been achieved ahead of full payor adoption, highlighting the potential for accelerating growth as we continue to expand market access during the third and fourth quarters. In addition, we have continued to build differentiated clinical evidence of YUTREPIA's safety and efficacy to treat PH-ILD through the ongoing, open-label ASCENT study, which fully enrolled last March (n=54). Interim analyses of eligible patients at Week 8 and Week 16 reinforced YUTREPIA's tolerability profile at higher doses and showed sustained median improvements in six-minute walk distance (6MWD) of 21.5 meters at Week 8 and 31.5 meters at Week 16. Importantly, patients titrated to a median dose of 132.5mcg at Week 8 and 159mcg at Week 16 with no change in mean cough score. There were no discontinuations stemming from drug-related adverse events, such as cough or throat irritation. More detailed clinical findings will be presented at medical conferences in September and October of 2025. With this strong early commercial execution, compelling clinical evidence, and financial flexibility through our recent funding under our financing agreement (HCR Agreement) with Healthcare Royalty (HCRx), we are well positioned to scale access to YUTREPIA, expand our clinical programs, and deliver durable value for patients and shareholders.' Second Quarter and Recent Corporate Highlights Second Quarter 2025 Financial Results Cash and cash equivalents totaled $173.4 million as of June 30, 2025, compared to $176.5 million as of December 31, 2024. Product revenue, net, was $6.5 million for the three months ended June 30, 2025. Following receipt of full FDA approval for YUTREPIA on May 23, 2025, we began shipping YUTREPIA to our customers in the United States in June 2025. We did not recognize any product revenue during the three months ended June 30, 2024. Service revenue, net, was $2.3 million for the three months ended June 30, 2025, compared to $3.7 million for the three months ended June 30, 2024. Service revenue, net related primarily to the promotion agreement with Sandoz, Inc. pursuant to which we share profits from the sale of Treprostinil Injection in the United States (Promotion Agreement). The decrease of $1.4 million was primarily due to the impact of unfavorable gross-to-net returns and managed care adjustments recorded in the current year. Cost of product sales was $0.2 million for the three months ended June 30, 2025 and related to sales of YUTREPIA. We did not record any cost of product sales for the three months ended June 30, 2024. Cost of service revenue was $1.3 million for the three months ended June 30, 2025, compared to $1.5 million for the three months ended June 30, 2024. Cost of service revenue related to the Promotion Agreement as noted above. Research and development expenses were $6.0 million for the three months ended June 30, 2025, compared to $9.4 million for the three months ended June 30, 2024. The decrease of $3.4 million or 36% was primarily due to a $2.7 million decrease in personnel expenses (including stock-based compensation) due to a shift from activities related to research and development to the commercialization of YUTREPIA, a $1.0 million decrease in expenses related to our YUTREPIA research and development activities, and a $0.4 million decrease in facilities and infrastructure expenses. These decreases were offset by a $1.1 million increase in clinical expenses for our L606 program, primarily related to our planned global pivotal study for the treatment of PH-ILD. Selling, general and administrative expenses were $38.8 million for the three months ended June 30, 2025, compared to $19.9 million for the three months ended June 30, 2024. The increase of $18.9 million or 95% was primarily due to a $8.8 million increase in personnel expenses (including stock-based compensation) driven by higher headcount and a shift from activities related to research and development to the commercialization of YUTREPIA, a $5.8 million increase in legal fees related to our ongoing YUTREPIA-related litigation, a $2.3 million increase in commercial and consulting expenses to support the commercialization of YUTREPIA, and a $1.3 million increase in facilities and infrastructure expenses. Total other expense, net was $4.1 million for the three months ended June 30, 2025, compared with $1.5 million for the three months ended June 30, 2024. The increase of $2.6 million was primarily attributable to the higher borrowings under the HCR Agreement. Net loss for the three months ended June 30, 2025, was $41.6 million or $0.49 per basic and diluted share, compared to a net loss of $28.7 million, or $0.38 per basic and diluted share, for the three months ended June 30, 2024. Webcast Information Liquidia will host a live webcast at 8:30 a.m. Eastern Time on August 12, 2025, to discuss the second quarter financial results and corporate update. The webcast will be available on Liquidia's website at A rebroadcast of the event will be available and archived for a period of one year at the same location. About YUTREPIA™ (treprostinil) Inhalation Powder YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia's PRINT® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies. About L606 (liposomal treprostinil) Inhalation Suspension L606 is an investigational, sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer. The L606 suspension uses Pharmosa Biopharm's proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with a planned global pivotal placebo-controlled efficacy study for the treatment of PH-ILD. About Treprostinil Injection Treprostinil Injection is the first-to-file, fully substitutable generic treprostinil for parenteral administration. Treprostinil Injection contains the same active ingredient, same strengths, same dosage form and same inactive ingredients as Remodulin® (treprostinil) and is offered to patients and physicians with the same level of service and support, but at a lower price than the branded drug. Liquidia PAH promotes the appropriate use of Treprostinil Injection for the treatment of PAH in the United States in partnership with its commercial partner, Sandoz, who holds the Abbreviated New Drug Application (ANDA) with the FDA. About Pulmonary Arterial Hypertension (PAH) Pulmonary arterial hypertension (PAH) is a rare, chronic, progressive disease caused by hardening and narrowing of the pulmonary arteries that can lead to right heart failure and eventually death. Currently, an estimated 45,000 patients are diagnosed and treated in the United States. There is currently no cure for PAH, so the goals of existing treatments are to alleviate symptoms, maintain or improve functional class, delay disease progression and improve quality of life. About Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) Pulmonary hypertension (PH) associated with interstitial lung disease (ILD) includes a diverse collection of up to 150 different pulmonary diseases, including interstitial pulmonary fibrosis, chronic hypersensitivity pneumonitis, connective tissue disease-related ILD, and chronic pulmonary fibrosis with emphysema (CPFE) among others. Any level of PH in ILD patients is associated with poor 3-year survival. A current estimate of PH-ILD prevalence in the United States is greater than 60,000 patients, though actual prevalence in many of these underlying ILD diseases is not yet known due to factors including underdiagnosis and lack of approved treatments until March 2021 when inhaled treprostinil was first approved for this indication. About Liquidia Corporation Liquidia Corporation is a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease. The company's current focus spans the development and commercialization of products in pulmonary hypertension and other applications of its proprietary PRINT® Technology. PRINT enabled the creation of Liquidia's first approved product, YUTREPIA™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company is also developing L606, an investigational sustained-release formulation of treprostinil administered twice-daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit Remodulin®, Tyvaso® and Tyvaso DPI® are registered trademarks of United Therapeutics Corporation. Cautionary Statements Regarding Forward-Looking Statements This press release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts, including statements regarding our future results of operations and financial position, our strategic and financial initiatives, our business strategy and plans and our objectives for future operations, are forward-looking statements. Such forward-looking statements, including statements regarding clinical trials, clinical studies and other clinical work (including the funding therefor, anticipated patient enrollment, safety data, study data, trial outcomes, timing or associated costs), regulatory applications and related submission contents and timelines, the timelines or outcomes related to patent litigation with United Therapeutics in the U.S. District Court for the District of Delaware and U.S. District Court for the Middle District of North Carolina, or other litigation between Liquidia and United Therapeutics or others, including rehearings or appeals of decisions in any such proceedings, the issuance of patents by the USPTO and our ability to execute on our strategic or financial initiatives, the potential for additional funding under the HCR Agreement, our anticipated use of net proceeds funded under the HCR Agreement, our estimates regarding future expenses, capital requirements and needs for additional financing, and potential revenue and profitability of YUTREPIA involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. YUTREPIA's approval and our launch of YUTREPIA remain subject to ongoing litigation in which United Therapeutics is seeking injunctive relief, which could block our ability to continue to sell YUTREPIA for one or both of PAH and PH-ILD. The words 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'would,' and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks discussed in our filings with the SEC, as well as a number of uncertainties and assumptions. Moreover, we operate in a very competitive and rapidly changing environment and our industry has inherent risks. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Nothing in this press release should be regarded as a representation by any person that these goals will be achieved, and we undertake no duty to update our goals or to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise. Financial Statement Revision During the three months ended March 31, 2025, we identified immaterial errors in our accounting treatment of the fourth and fifth amendments to the HCR Agreement. We voluntarily revised our previously issued 2024 annual consolidated financial statements to correct the immaterial errors and disclosed the impacts to our quarterly financial statements for the respective 2024 interim periods in our Current Report on Form 8-K filed on May 8, 2025. As a result of the revision, the loss on extinguishment has been eliminated and an adjustment to interest expense resulting from the modifications has been recorded, with corresponding adjustments to the long-term debt and accumulated deficit accounts. The financial statement line items as of and for the three months ended June 30, 2024 in the financial statements presented in this press release reflect such revisions. Contact Information Investors: Jason Adair Chief Business Officer 919.328.4350 [email protected] Media: Patrick Wallace Director, Corporate Communications 919.328.4383 [email protected]
Yahoo
2 hours ago
- Yahoo
Rising Popularity of Immersive Technologies Generates Demand for VR/AR-Ready Video Delivery Platforms
The Video Platform as a Service (VPaaS) market presents expansive opportunities driven by increased demand for scalable, secure, and customizable video infrastructure. Growth areas include public and private cloud deployments, with significant traction in sectors like education, healthcare, and corporate services. Customizable video experiences and advanced security are key differentiators. Video Platform as a Service (VPaaS) Market Dublin, Aug. 12, 2025 (GLOBE NEWSWIRE) -- The "Video Platform as a Service (VPaaS) - Global Strategic Business Report" report has been added to global market for Video Platform as a Service (VPaaS) was estimated at US$7.4 Billion in 2024 and is projected to reach US$24.5 Billion by 2030, growing at a CAGR of 22.2% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. What Is Powering the Market's Upward Trajectory and Unfolding Its Next Growth Phase?The growth in the Video Platform as a Service (VPaaS) market is driven by several factors deeply rooted in technological evolution, enterprise digital transformation, and consumer media habits. One of the most significant drivers is the widespread digitalization of industries that have traditionally been reliant on face-to-face interaction. Sectors such as education, healthcare, retail, and corporate services are rapidly integrating video into their operations to enhance engagement, deliver services, and streamline communication. The normalization of remote work and virtual collaboration has also increased the enterprise demand for secure, scalable, and high-concurrency video platforms. From a technology standpoint, advancements in artificial intelligence and machine learning are enabling features such as automated transcription, facial recognition, content moderation, and smart recommendations, adding value to basic video delivery. Additionally, the shift toward cloud-native architectures is making VPaaS platforms more agile, scalable, and cost-efficient for businesses of all sizes. Mobile-first behavior, particularly in high-growth regions of Asia, Africa, and Latin America, is pushing companies to adopt video solutions that cater to varying screen sizes and data constraints. This trend is especially strong in the e-commerce sector, where influencer marketing and livestream selling are gaining momentum. In education and training, asynchronous video delivery is addressing the growing need for flexible learning environments. Meanwhile, the surge in user-generated content and creator monetization has created new demands for platforms that can handle large volumes of uploads, dynamic community interactions, and real-time streaming. Together, these forces are shaping the VPaaS market into a dynamic ecosystem that is not only growing in size but also expanding in strategic importance across the digital economy. How Are Evolving Content Ecosystems Fueling the Need for Scalable Video Infrastructure?In a rapidly digitizing world where video consumption dominates internet traffic, the demand for seamless and scalable video infrastructure has escalated dramatically. Video Platform as a Service (VPaaS) has become an essential enabler for companies looking to integrate video capabilities such as real-time streaming, hosting, editing, analytics, and transcoding directly into their applications without the burden of building expensive backend infrastructure. The growth of Over-the-Top (OTT) services, the explosion of user-generated content, and the rising popularity of live-streamed events have accelerated the adoption of VPaaS across sectors. Media and entertainment companies are no longer the sole users of such platforms. Educational institutions, healthcare providers, corporate enterprises, and public sector agencies are all embedding video into their digital experiences to meet new expectations for communication, marketing, and customer engagement. The transition to hybrid work and learning models has made live and on-demand video features essential for business continuity and knowledge delivery. VPaaS providers are meeting this demand by offering flexible APIs and SDKs that allow organizations to integrate features such as adaptive bitrate streaming, audience polling, multi-device compatibility, and real-time chat. These technical capabilities support a wide range of use cases including virtual classrooms, telehealth appointments, livestream shopping, virtual corporate town halls, and interactive webinars. As video becomes central to how information is consumed and shared, VPaaS offers a scalable, customizable foundation that enables companies to grow their video footprint rapidly and efficiently across platforms and Is Driving the Customization Surge in Video-Driven Consumer Experiences?Digital consumers are no longer satisfied with generic video interactions. They expect highly personalized, interactive, and visually cohesive experiences that reflect the brand identity and anticipate user preferences. This shift in expectations is fueling a surge in demand for customization within the VPaaS market. Businesses across industries are seeking VPaaS solutions that allow them to deliver branded, responsive, and interactive video environments. E-commerce brands are embedding live shoppable videos into their websites and apps, enabling viewers to interact with hosts, ask questions, and make purchases without leaving the video player. Education platforms are tailoring course content with adaptive navigation, personalized assessments, and language options to accommodate diverse learners. In sectors such as fitness, online coaching, and live entertainment, VPaaS is being used to create immersive multi-camera experiences with interactive overlays and dynamic user input. Innovations like augmented and virtual reality support, gamified learning environments, and AI-generated content recommendations are now being layered into video workflows. Furthermore, machine learning-powered analytics provide insights into viewer behavior, engagement rates, and content effectiveness, allowing businesses to continually refine their video strategies. The rise in mobile consumption has also made it essential for VPaaS providers to support responsive design, device optimization, and bandwidth-adaptive streaming. These features help businesses deliver high-quality video experiences even in low-connectivity environments. As customer expectations continue to evolve, the capacity of VPaaS platforms to provide deep customization is emerging as a major differentiator in a competitive market. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Agora, AWS Elemental / Amazon Web Services, Bitmovin, Brightcove and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. Key Insights: Market Growth: Understand the significant growth trajectory of the Public Cloud Deployment segment, which is expected to reach US$15.2 Billion by 2030 with a CAGR of a 20.3%. The Private Cloud Deployment segment is also set to grow at 25.8% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, estimated at $2.0 Billion in 2024, and China, forecasted to grow at an impressive 29.3% CAGR to reach $5.8 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Scope Of Study: Deployment (Public Cloud Deployment, Private Cloud Deployment) Application (Broadcasting Video Communication Application, Real-time Video communication Application, Video Content Management Application, Other Applications) End-Use (Social End-Use, Media & Entertainment End-Use, Education End-Use, Healthcare End-Use, Banking & Finance End-Use, Other End-Uses) Key Attributes: Report Attribute Details No. of Pages 384 Forecast Period 2024 - 2030 Estimated Market Value in 2024 7.4 Billion Forecasted Market Value by 2030 24.5 Billion Compound Annual Growth Rate 22.2% Regions Covered Global Key Topics Covered: MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Video Platform as a Service (VPaaS) - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Increasing Enterprise Focus on Remote Collaboration Propels Growth of VPaaS Solutions Booming Creator Economy Throws the Spotlight on Scalable, Monetizable Video Platforms Integration with AI and ML Engines Expands Addressable Market Opportunity for VPaaS Rising Demand for Interactive Video Experiences Strengthens Business Case for Real-Time Streaming Services Here`s How Vertical-Specific Applications in Healthcare, Education, and Retail Drive Adoption of VPaaS Global 5G Rollout Accelerates Demand for Low-Latency, High-Resolution Video Delivery Platforms Growing Emphasis on Customer Engagement Strategies Spurs Growth of Embedded Video Use Cases Emergence of API-First Architectures Drives Adoption Among Developer-Led Organizations Subscription Fatigue and Content Saturation Challenge Differentiation, Forcing Innovation in Platform Features Cloud-Native Infrastructure Trends Sustain Growth in Highly Elastic VPaaS Deployments Here`s the Story: How Video-First Digital Transformation is Reshaping B2B Communication Models Rising Popularity of Immersive Technologies Generates Demand for VR/AR-Ready Video Delivery Platforms Proliferation of Edge Computing Architectures Unlocks New Use Cases for Ultra-Low Latency Video Applications FOCUS ON SELECT PLAYERS |Some of the 42 companies featured in this Video Platform as a Service (VPaaS) market report include: Agora AWS Elemental / Amazon Web Services Bitmovin Brightcove Cloudinary Gumlet JW Player Kaltura Video Cloud Microsoft Azure Media Services Muvi (including Muvi One/Flex) Mux Telestream (Vantage Cloud) Twilio Vimeo Vonage Communications APIs Watchity Wistia Ziggeo For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Video Platform as a Service (VPaaS) Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
